Department of Medicine
Faculty Profiles by Division

Department of Medicine

Faculty Profiles

[Return To Index page]
photo Michael Boyiadzis, MD,MHSc


Associate Professor of Medicine

Director, Clinical and Translational Research Program

University of Pittsburgh Cancer Institute


Phone: 412-623-0040

Office: UPMC Cancer Pavilion
5150 Centre Avenue, Suite 564
Pittsburgh, PA 15232
Phone: 412-623-0040
Fax: 412-648-6579
Administrative Assistant:
Lois Malehorn
Address: 5150 Centre Avenue
Pittsburgh, PA 15232
Phone: 412-648-6589
Education and Training
MD, University Medical School of Debrecen, 1995
MHSc, Duke University School of Medicine, 2005
Internal Medicine Resident, St. Agnes Hospital , Maryland, 2000
Chief Medical Resident, St. Agnes Hospital , Maryland, 2001
Hematology-Oncology Fellow, National Cancer Institute, Maryland, 2005
Research Interest
Dr. Boyiadzis' research focuses on natural killer cell biology, immunotherapy and hematopoeitc stem cell transplantation.
Clinical Interest
My clinical research efforts have been focused on the design and development of new treatment approaches, including immunotherapy and antibodies, in AML. More recently, I have been investigating the role exosomes play in AML-associated immune suppression and considering mechanisms that could be developed to reverse exosome-mediated silencing of immune cells in AML.
For my complete bibliography, Click Here.
Selected Publications:
Boyiadzis M, Memon S, Carson J, Allen K, Vance B, Dean R, Bishop M, Gress R, Hakim T. Up-regulation of NK cell activating receptors post-transplant associated with elevated IL-15 levels. Biology of Blood and Marrow Transplantation. 2008; 14: 290-300.
Szczepanski M, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, Foon K, Whiteside T, Boyiadzis M. Increased frequency and suppression by regulatory T cells in patients with acute myeloid leukemia. Clinical Cancer Research. 2009; 15(10): 3325-32.
Szczepanski MJ, Szajnik M, Welsh A, Foon KA, Whiteside TL, Boyiadzis M. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunology Immunotherapy. 2010; 59(1): 73-9.
Boyiadzis M, Redner R, Raptis A, Hou JZ, Agha M, Foon K. Gemtuzumab ozogamicin, mitoxantrone and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy. Annals of Hematology. 2011; 90(6): 733-5.
Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera of acute myeloid leukemia patients suppresses NK cell function via membrane-associated TGF-ß1. Haematologica. 2011; 96(9): 1302-9.
Hong CS, Muller L, Whiteside TL, Boyiadzis M. Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia. Frontiers in Immunology. 2014; 10(5): 160.
Boyiadzis M, Arora M, Klein JP, Hasserbroek A, Hemmer M, Urbano-Ispicua AU, Antin JH, Bolwell BJ, Cahn JY, Cairo MS, Cutler CS, Flowers ME, Gale RP, Herzig R, Isola LM, Jacobsohn DA, Jagasia MH, Klumpp TR, Lee SJ, Petersdorf EW, Spellman SR, Schouten HC, Verdonck LF, Wingard JR,, Weisdorf DJ, Horowitz MM, Pavletic SZ. Impact of chronic graft-versus-host disease on late relapse and survival after myeloablative allogeneic hematopoietic cell transplantation for leukemia. Clinical Cancer Research. 2015; 1(21): 2020-8.
Notable Achievements
Editor, Hematology-Oncology Therapy, 1st edition, McGraw Hill, 2007
Editor, Hematology-Oncology Therapy , 2nd edition, McGraw Hill, 2014
Hematology Course Director, University of Pittsburgh School of Medicine, Academic years, 2008-2009
Editorial Board Member, Oncology Research, 2015-present
Editorial Board Member, Experimental Biology and Medicine, 2006-2012
Member, American Society of Hematology, 2002-present
Member, American Society of Clinical Oncology, 2001-present
Member, American College of Physicians, 2003-present